Examples of 'pyroglutamate' in a sentence
Meaning of "pyroglutamate"
Pyroglutamate (noun): A derivative of glutamic acid that can be found in certain proteins and can act as a neurotransmitter in the brain
Show more definitions
- Any salt or ester of pyroglutamic acid
- To modify by reaction with a pyroglutamic acid derivative
How to use "pyroglutamate" in a sentence
Basic
Advanced
pyroglutamate
Pyroglutamate is found in many proteins including bacteriorhodopsin.
The amounts of vortioxetine pyroglutamate are indicated as free base.
Pyroglutamate formation can be performed in vivo or in vitro.
These mutation is introduced to prevent possible pyroglutamate formation.
Sodium pyroglutamate has the following structure,.
A residual formation of small amounts of pyroglutamate was still observed.
Preferred permeation enhancers for administering fentanyl include monoglycerides and lauryl pyroglutamate.
Pyroglutamate is known to have a number of remarkable cognitive-enhancing effects.
Vortioxetine is initially brought into solution as the pyroglutamate salt.
The pyroglutamate is available commercially, and has also been synthesized by a previously unpublished process.
This resulted in a shift in retention time suggesting removal of a pyroglutamate residue.
Less pyroglutamate is formed in L-histidine compared to phosphate buffer.
A preferred permeation enhancer according to this invention comprises lauryl pyroglutamate.
Therefore, such antibodies were first treated with pyroglutamate aminopeptidase and thereafter sequenced.
The permeation enhancer may be selected from the group consisting of monoglycerides and lauryl pyroglutamate.
See also
Pyroglutamate may be included as the N-terminal residue of the peptide.
The residue was inferred to be glutamine from results of treatment with pyroglutamate aminopeptidase.
These modifications prevent pyroglutamate formation from cyclization of N-terminal glutamine.
Detailed Description of the Invention The present invention relates to pyroglutamate salts of vortioxetine.
Formula of arginine pyroglutamate and L-ornithine, important factors in muscle metabolism.
One nmol samples of heparinases II and III were used for deblocking with pyroglutamate aminopeptidase.
The enzyme pyroglutamate aminopeptidase can restore a free N-terminus by cleaving off the pyroglutamate residue.
The shell comprises a humectant, preferably sodium pyroglutamate.
In the above sequences pGlu represents pyroglutamate and DpGlu represents D-pyroglutamate.
Accordingly, in one embodiment, the invention relates to vortioxetine pyroglutamate.
This result suggests a blocked N-terminus, likely a pyroglutamate site based on the gene sequence.
Preferably, the permeation enhancer is glycerol monolaurate, or lauryl pyroglutamate.
Introduction of pyroglutamate at the N-terminus can protect the analog against N-terminal hydrolysis.
Furthermore, no amino acid sequence was obtained after pyroglutamate aminopeptidase treatment.
N-terminus de-blocking with pyroglutamate amino peptidase is carried out according to manufacturer 's instructions.
Accordingly, the same analysis was repeated after treatment with pyroglutamate aminopeptidase.
Twenty subjects were treated with pyroglutamate and 20 with a placebo over a period of 60 days.
In one embodiment, the invention relates to a pharmaceutical composition comprising vortioxetine pyroglutamate.
Another form of degradation is the formation of pyroglutamate from N-terminal Glu or Gin.
In one embodiment, the invention provides an enteric coated formulation comprising vortioxetine pyroglutamate.
Humectants such as glycerol, sodium pyroglutamate and sodium lactate ;.
The data reported in Example 18 shows the dissolution rate for vortioxetine HBr and vortioxetine pyroglutamate.
A pre-blend was prepared by mixing vortioxetine pyroglutamate with microcrystalline cellulose in a 1:1 ratio.
Control samples were produced by mock deblocking 1 nmol protein samples without adding pyroglutamate aminopeptidase.
The formation of pyroglutamate in the sample can e.g. be measured by RP-HPLC.
In one embodiment, the invention relates to vortioxetine pyroglutamate for use in therapy.
At all time points, less pyroglutamate was present in the L-histidine buffer.
The Q1E mutation was introduced in order to prevent pyroglutamate formation.
This was the case for the pyroglutamate modification which appeared as a post-peak ( cf . ( iii ) above ).
In particular, during heat sterilization of glutamine solutions, pyroglutamate and glutamic acid may form.
For the avoidance of doubt, “ salt ” does not include vortioxetine pyroglutamate.
Furthermore, MCP-1 carries a pyroglutamate at its amino terminus.
ClEF, a post peak is being formed which is believed to correspond to the pyroglutamate variant.
A method according to claim 14 wherein the permeation enhancer is glycerol monolaurate, or lauryl pyroglutamate.
The mixture was stirred at 52 °C until the pyroglutamate salt precipitated.
